BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BioCentury | Oct 25, 2019
Product Development

Deciding factors in the shifting MS treatment landscape

The efficacy and convenience advantages that established oral medicines as the go-to therapy in multiple sclerosis are the same factors now squeezing them out. Two years post-launch, the success of injectable Ocrevus ocrelizumab from Roche...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BC Week In Review | Jan 26, 2018
Company News

Novartis to begin ex-U.S. compassionate use program for Arzerra

Genmab A/S (CSE:GEN; Pink:GMXAY) said partner Novartis AG (NYSE:NVS; SIX:NOVN) will begin offering Arzerra ofatumumab to patients outside the U.S. through compassionate use programs. Genmab said that over the past five years, additional CLL drugs...
BC Week In Review | Jan 19, 2018
Clinical News

Roche's Ocrevus receives EU approval for MS

The European Commission approved Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat the relapsing and primary progressive forms of multiple sclerosis (PPMS). Roche said Ocrevus is the first and only disease-modifying drug for PPMS approved...
BC Extra | Jan 12, 2018
Company News

Roche's Ocrevus receives EU approval for MS

Roche (SIX:ROG; OTCQX:RHHBY) said the European Commission approved Ocrevus ocrelizumab to treat the relapsing and primary progressive forms of multiple sclerosis (PPMS). Roche said Ocrevus is the first and only disease-modifying drug for PPMS approved...
BioCentury | Oct 28, 2017
Product Development

Chinks in the armor

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since...
BC Week In Review | Oct 27, 2017
Clinical News

TG Therapeutics modifies Phase IIb trial of TG-1101

TG Therapeutics Inc. (NASDAQ:TGTX) said an independent DSMB recommended discontinuation of the TGR-1202 (umbralisib) monotherapy arm of the Phase IIb UNITY-NHL trial in the diffuse large B cell lymphoma (DLBCL) cohort after a pre-planned interim...
BC Week In Review | Oct 27, 2017
Clinical News

TG Therapeutics modifies Phase IIb trial of TGR-1202

TG Therapeutics Inc. (NASDAQ:TGTX) said an independent DSMB recommended discontinuation of the TGR-1202 (umbralisib) monotherapy arm of the Phase IIb UNITY-NHL trial in the diffuse large B cell lymphoma (DLBCL) cohort after a pre-planned interim...
BioCentury | Oct 20, 2017
Finance

Early opportunity

Preliminary data from ongoing studies of lead candidate Hu5F9-G4 enabled Forty Seven Inc. to raise a $75 million series B round sooner than expected. The new funds will allow Forty Seven to launch and complete...
Items per page:
1 - 10 of 49